Tag Archives: Masitinib

Webcast Presentation – Masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indications

28/02/2022 – Presentation of the webcast held on February 28, 2022 on masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indications

Financing of a 8.5 million dollars through the issuance of convertible bonds with attached warrants

28/02/2022 – AB Science announces today that it reached an agreement with a historical investor on a financing of USD 8.5 million through the issuance of bonds convertible into new ordinary shares with attached warrants

AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment ALS in Canada and to provide an update on its clinical program in all indications

24/02/2022 – AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment of amyotrophic lateral sclerosis (ALS) in Canada under the NOC/c procedure and to provide an update on its clinical program in all indications

Publication of the masitinib positive pivotal phase 3 trial in progressive forms of multiple sclerosis in the journal Neurology® Neuroimmunology & Neuroinflammation

22/02/2022 – AB Science announced the publication of results from its positive pivotal phase 3 trial of masitinib in progressive forms of multiple sclerosis in the peer-reviewed journal Neurology® Neuroimmunology & Neuroinflammation

Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of ALS under the Notice of Compliance with Conditions (NOC/c) policy

21/02/2022 – AB Science today announces that Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of amyotrophic lateral sclerosis (ALS) under the Notice of Compliance with Conditions (NOC/c) policy

Clarification following the February 11, 2022 public hearing of the Enforcement Committee of the French Market Regulator (AMF)

12/02/2022 – AB Science wishes to provide clarifications following press articles published after the public hearing of the Enforcement Committee of the French market regulator (AMF) on Friday, February 11, 2022

AB Science to present on its Amyotrophic Lateral Sclerosis (ALS) development program at the 2022 ALS Drug Development Summit

07/02/2022 – AB Science will deliver a presentation on the Amyotrophic Lateral Sclerosis (ALS) masitinib development program at the 2022 ALS Drug Development Summit

AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the Swedish Medical Products Agency

02/02/2022 – AB Science today announces that it has been authorized by the Swedish Medical Products Agency, to initiate a Phase III study (AB20009) evaluating masitinib in patients with Primary Progressive Multiple Sclerosis (PPMS) or non-active Secondary Progressive Multiple Sclerosis (nSPMS)

AB Science granted authorization to initiate Phase II study in patients with severe mast cell activation syndrome by the French Health Authority (ANSM)

19/01/2022 – AB Science today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase II study (AB20006) in patients with severe mast cell activation syndrome

AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the French Health Authority (ANSM)

03/01/2022 – AB Science today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase III study (AB20009) evaluating masitinib in patients with Primary Progressive Multiple Sclerosis (PPMS) or non-active Secondary Progressive Multiple Sclerosis (nSPMS)